Altvater, Bianca http://orcid.org/0000-0003-4936-4879
Kailayangiri, Sareetha
Spurny, Christian
Flügge, Maike
Meltzer, Jutta
Greune, Lea
Urban, Katja
Schwöppe, Christian
Brand, Caroline
Schliemann, Christoph
Hintelmann, Heike
Harrach, Saliha
Hartmann, Wolfgang http://orcid.org/0000-0002-7609-5021
Abken, Hinrich
Kuehle, Johannes
Schambach, Axel
Görlich, Dennis http://orcid.org/0000-0002-2574-9419
Berdel, Wolfgang E. http://orcid.org/0000-0002-3030-6567
Rossig, Claudia http://orcid.org/0000-0002-8672-5285
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (RO 2402/8-1/BE 822/10-1, INST 211/718-1 FUGG, RO 2402/8-1/BE 822/10-1)
Article History
Received: 8 March 2023
Revised: 13 June 2023
Accepted: 21 June 2023
First Online: 30 June 2023
Competing interests
: W.E.B. holds patents on vascular targeting and patent applications on electrostatic nanocarrier technology. He is an advisor and shareholder of Philogen S.p.A., Siena, Italy, and he is CEO and co-owner of the biotech company Anturec Pharmaceuticals GmbH, which owns the IP for tTF-NGR. C.Schw. is co-owner of the biotech company Anturec Pharmaceuticals GmbH, which owns the IP for tTF-NGR. H.A., J.K. and A.S. have submitted a patent application describing the all-in-one-vector technology. None of the other authors has any potential financial conflicts of interest.
: The use of blood samples from healthy donors was approved by the Ethics Board Westphalia Lippe.